Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Editorial Open access Sep 2026

Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”

The treatment landscape for metastatic renal cell carcinoma (mRCC) has changed significantly with the advent of combination therapies based on immune checkpoint inhibitors (ICIs). Currently, nivolumab plus ipilimumab (NIVO+IPI) and ICI plus tyrosine kinase inhibitor (IO–TKI) combination therapies are widely used as fir...

H. Hirata · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.